Insider Selling: Ionis Pharmaceuticals Inc (IONS) Chairman Sells 22,000 Shares of Stock

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 22,000 shares of the stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $50.01, for a total value of $1,100,220.00. Following the completion of the sale, the chairman now owns 58,014 shares in the company, valued at approximately $2,901,280.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ionis Pharmaceuticals Inc (IONS) traded up $0.05 on Friday, reaching $53.22. The company’s stock had a trading volume of 946,534 shares, compared to its average volume of 1,066,893. Ionis Pharmaceuticals Inc has a 52 week low of $37.26 and a 52 week high of $65.51. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21. The stock has a market capitalization of $6,620.00, a price-to-earnings ratio of 380.14 and a beta of 2.86.

IONS has been the topic of a number of recent analyst reports. Stifel Nicolaus reiterated a “hold” rating and issued a $50.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price target on the stock in a research note on Friday, October 27th. BidaskClub upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th. Morgan Stanley raised their price target on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. Finally, BMO Capital Markets raised their price target on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, November 8th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $50.76.

A number of institutional investors and hedge funds have recently bought and sold shares of IONS. Russell Investments Group Ltd. boosted its holdings in Ionis Pharmaceuticals by 21.4% in the second quarter. Russell Investments Group Ltd. now owns 20,077 shares of the company’s stock worth $1,021,000 after acquiring an additional 3,538 shares in the last quarter. Rothschild Asset Management Inc. boosted its holdings in Ionis Pharmaceuticals by 10.8% in the third quarter. Rothschild Asset Management Inc. now owns 281,068 shares of the company’s stock worth $14,250,000 after acquiring an additional 27,426 shares in the last quarter. Bank of Nova Scotia acquired a new stake in Ionis Pharmaceuticals in the second quarter worth about $1,526,000. 361 Capital LLC acquired a new stake in Ionis Pharmaceuticals in the second quarter worth about $1,596,000. Finally, GSA Capital Partners LLP acquired a new stake in Ionis Pharmaceuticals in the second quarter worth about $1,096,000. Institutional investors own 91.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Ionis Pharmaceuticals Inc (IONS) Chairman Sells 22,000 Shares of Stock” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://ledgergazette.com/2018/01/12/ionis-pharmaceuticals-inc-ions-chairman-sells-1100220-00-in-stock.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply